Issues for new antiepilepsy drug development

Michele Simonato, Jacqueline A. French, Aristea S. Galanopoulou, Terence J. O'Brien

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose of Review: Preclinical research in epileptology has been very successful in producing effective drugs. Unfortunately, however, seizures are still not adequately controlled in a third of the affected individuals, and comorbidities still impose a major burden on the quality of life. New preclinical and clinical drug development strategies are needed to identify drugs that target these unmet medical needs. Purpose of Review: Even in recent years, the antiseizure approach based on screenings has contributed to the identification of new drugs. Thus, it should not be abandoned. However, we propose that a radically new approach, specifically designed to tackle the existing gaps in care, should be developed to complement the traditional screening. This new approach will require integrated strategies for preclinical screening and experimental trial design. In this review, we will attempt to address some of the issues that must be resolved to engage this effort. Are there suitable models to tackle the unmet therapeutic needs in epilepsy? Are there ways to de-risk the transition from preclinical to clinical studies? Are there ways to improve the efficiency of clinical trials and to design ad hoc trials for the unmet therapeutic needs? Summary: Development and validation of a new, integrated strategy for antiepilepsy drug development is needed to identify truly innovative drugs.

Original languageEnglish (US)
Pages (from-to)195-200
Number of pages6
JournalCurrent Opinion in Neurology
Volume26
Issue number2
DOIs
StatePublished - Apr 2013

Fingerprint

Pharmaceutical Preparations
Comorbidity
Epilepsy
Seizures
Research Design
Quality of Life
Clinical Trials
Therapeutics
Research
Clinical Studies

Keywords

  • antiepileptogenesis
  • antiseizure drug
  • biomarker
  • comorbidity
  • disease modification

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Issues for new antiepilepsy drug development. / Simonato, Michele; French, Jacqueline A.; Galanopoulou, Aristea S.; O'Brien, Terence J.

In: Current Opinion in Neurology, Vol. 26, No. 2, 04.2013, p. 195-200.

Research output: Contribution to journalArticle

Simonato, Michele ; French, Jacqueline A. ; Galanopoulou, Aristea S. ; O'Brien, Terence J. / Issues for new antiepilepsy drug development. In: Current Opinion in Neurology. 2013 ; Vol. 26, No. 2. pp. 195-200.
@article{2dec398051cd4881a161424f9427f943,
title = "Issues for new antiepilepsy drug development",
abstract = "Purpose of Review: Preclinical research in epileptology has been very successful in producing effective drugs. Unfortunately, however, seizures are still not adequately controlled in a third of the affected individuals, and comorbidities still impose a major burden on the quality of life. New preclinical and clinical drug development strategies are needed to identify drugs that target these unmet medical needs. Purpose of Review: Even in recent years, the antiseizure approach based on screenings has contributed to the identification of new drugs. Thus, it should not be abandoned. However, we propose that a radically new approach, specifically designed to tackle the existing gaps in care, should be developed to complement the traditional screening. This new approach will require integrated strategies for preclinical screening and experimental trial design. In this review, we will attempt to address some of the issues that must be resolved to engage this effort. Are there suitable models to tackle the unmet therapeutic needs in epilepsy? Are there ways to de-risk the transition from preclinical to clinical studies? Are there ways to improve the efficiency of clinical trials and to design ad hoc trials for the unmet therapeutic needs? Summary: Development and validation of a new, integrated strategy for antiepilepsy drug development is needed to identify truly innovative drugs.",
keywords = "antiepileptogenesis, antiseizure drug, biomarker, comorbidity, disease modification",
author = "Michele Simonato and French, {Jacqueline A.} and Galanopoulou, {Aristea S.} and O'Brien, {Terence J.}",
year = "2013",
month = "4",
doi = "10.1097/WCO.0b013e32835efe29",
language = "English (US)",
volume = "26",
pages = "195--200",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Issues for new antiepilepsy drug development

AU - Simonato, Michele

AU - French, Jacqueline A.

AU - Galanopoulou, Aristea S.

AU - O'Brien, Terence J.

PY - 2013/4

Y1 - 2013/4

N2 - Purpose of Review: Preclinical research in epileptology has been very successful in producing effective drugs. Unfortunately, however, seizures are still not adequately controlled in a third of the affected individuals, and comorbidities still impose a major burden on the quality of life. New preclinical and clinical drug development strategies are needed to identify drugs that target these unmet medical needs. Purpose of Review: Even in recent years, the antiseizure approach based on screenings has contributed to the identification of new drugs. Thus, it should not be abandoned. However, we propose that a radically new approach, specifically designed to tackle the existing gaps in care, should be developed to complement the traditional screening. This new approach will require integrated strategies for preclinical screening and experimental trial design. In this review, we will attempt to address some of the issues that must be resolved to engage this effort. Are there suitable models to tackle the unmet therapeutic needs in epilepsy? Are there ways to de-risk the transition from preclinical to clinical studies? Are there ways to improve the efficiency of clinical trials and to design ad hoc trials for the unmet therapeutic needs? Summary: Development and validation of a new, integrated strategy for antiepilepsy drug development is needed to identify truly innovative drugs.

AB - Purpose of Review: Preclinical research in epileptology has been very successful in producing effective drugs. Unfortunately, however, seizures are still not adequately controlled in a third of the affected individuals, and comorbidities still impose a major burden on the quality of life. New preclinical and clinical drug development strategies are needed to identify drugs that target these unmet medical needs. Purpose of Review: Even in recent years, the antiseizure approach based on screenings has contributed to the identification of new drugs. Thus, it should not be abandoned. However, we propose that a radically new approach, specifically designed to tackle the existing gaps in care, should be developed to complement the traditional screening. This new approach will require integrated strategies for preclinical screening and experimental trial design. In this review, we will attempt to address some of the issues that must be resolved to engage this effort. Are there suitable models to tackle the unmet therapeutic needs in epilepsy? Are there ways to de-risk the transition from preclinical to clinical studies? Are there ways to improve the efficiency of clinical trials and to design ad hoc trials for the unmet therapeutic needs? Summary: Development and validation of a new, integrated strategy for antiepilepsy drug development is needed to identify truly innovative drugs.

KW - antiepileptogenesis

KW - antiseizure drug

KW - biomarker

KW - comorbidity

KW - disease modification

UR - http://www.scopus.com/inward/record.url?scp=84874941208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874941208&partnerID=8YFLogxK

U2 - 10.1097/WCO.0b013e32835efe29

DO - 10.1097/WCO.0b013e32835efe29

M3 - Article

C2 - 23406913

AN - SCOPUS:84874941208

VL - 26

SP - 195

EP - 200

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

IS - 2

ER -